CANYON PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.canyonpharma.com
Clinical Trials
3
Active:1
Completed:1
Trial Phases
1 Phases
Phase 4:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 4
2 (100.0%)Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Canyon Pharmaceuticals, Inc.
- Target Recruit Count
- 516
- Registration Number
- NCT00913133
- Locations
- 🇺🇸
University of Colorado Health Science Center, Aurora, Colorado, United States
🇺🇸University of South Florida, Tampa General Hospital, Tampa, Florida, United States
🇺🇸Saint Joseph's Research Institute, Atlanta, Georgia, United States
A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome
Phase 4
Terminated
- Conditions
- Suspected Heparin-Induced Thrombocytopenia
- Interventions
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Canyon Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00787332
- Locations
- 🇺🇸
University of Colorado Health Science Center, Aurora, Colorado, United States
🇺🇸Washington Regional Cardiac Surgery, Washington, DC, District of Columbia, United States
🇺🇸Florida Hospital Cardiovascular Research, Orlando, Florida, United States
News
No news found